Why did Corcept Therapeutics (CORT) stock move recently?

On 7/28/2026, Corcept Therapeutics moved +3.4% — No specific company catalyst or news reported for July 28; the gain appears to reflect broader market or sector momentum following recent analyst earnings estimate upgrades. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Corcept Therapeutics (CORT) overvalued or fairly valued?

MarketChacha shows Corcept Therapeutics's valuation in context — a trailing P/E of about 218.9, a forward P/E of about 25.3, a price-to-book of about 17.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Corcept Therapeutics's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.35×) from reported figures — education, not a rating.

What is Corcept Therapeutics's revenue?

Corcept Therapeutics reported revenue of $761.4M for FY2025, with net profit of $99.7M, per official filings.

What is the share price of Corcept Therapeutics (CORT)?

Corcept Therapeutics last traded at $111.62 (-1.0% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Corcept Therapeutics

CORT · NYSE · Healthcare · United States

Snapshot

TickerCORT

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees730

HeadquartersRedwood City, United States

Websitewww.corcept.com

Filings tracked20

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Who owns it

Insiders11.4%
Institutions76.9%
Public & other11.6%

546 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.11.50%
Ingalls & Snyder LLC7.34%
Renaissance Technologies, LLC4.87%
Vanguard Portfolio Management LLC4.67%
Vanguard Capital Management LLC3.86%
Parallel Advisors, LLC3.67%
FMR, LLC3.09%
State Street Corporation3.03%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 8.9 points over the period — profitability is trending down.

Cash conversion1.35×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend22.0% → 13.1%

Margin has compressed by about 8.9 points over the period — profitability is trending down.

Return on equity15.4%

Latest ROE of 15.4% — capital is generating a healthy return.

Growth qualityrev 26% · PAT -3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $388.7M · EPS 1.21

Est. earnings growth +502.5%

Next fiscal year

Rev $1.7B · EPS 4.40

Est. earnings growth +104.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$761.4M

Net margin

13.1%

ROE

15.4%

Revenue CAGR (2y)

+25.6%

Profit CAGR (2y)

-3.1%

EPS (FY2025)

0.82

Net profit (FY2025)

$99.7M

Ask MarketChacha about CORT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
No specific company catalyst or news reported for July 28; the gain appears to reflect broader market or sector momentum following recent analyst earnings estimate upgrades.
· confidence: low
Jul 27, 2026
CORT fell on valuation concerns after recent Lifyorli approval and upward estimate revisions, with multiple analyses flagging the stock as potentially overvalued following its large prior run-up.
source 1 ↗source 2 ↗· confidence: medium
Jul 23, 2026
No specific catalyst identified in today's news or filings; CORT rose with momentum from its strong YTD outperformance ahead of its July 29 earnings report.
· confidence: low
Jul 22, 2026
No specific company catalyst or news event was reported on July 22, 2026; the decline appears to reflect broader market or sector movement following recent insider sales and earlier FDA-related developments.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$761.4M	$99.7M	0.82	13.1%	15.4%
FY2024	$675.0M	$141.2M	1.23	20.9%	20.8%
FY2023	$482.4M	$106.1M	0.94	22.0%	20.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$256.1M	$43.0M	0.36	16.8%
2026Q1	$164.9M	$-31.8M	-0.30	-19.3%
2025Q3	$207.6M	$19.7M	0.16	9.5%
2025Q2	$194.4M	$35.1M	0.29	18.1%
2025Q1	$157.2M	$20.5M	0.17	13.1%
2024Q3	$182.5M	$47.2M	0.41	25.9%
2024Q2	$163.8M	$35.5M	0.32	21.7%
2024Q1	$146.8M	$27.8M	0.25	18.9%
2023Q3	$123.6M	$31.4M	0.28	25.4%
2023Q2	$117.7M	$27.5M	0.25	23.4%
2023Q1	$105.7M	$15.9M	0.14	15.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/29/2026material
10-Q filing
SEC7/29/2026
8-K — Other events, Exhibits
SEC6/17/2026material
8-K — Other events
SEC6/3/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/28/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Other events, Exhibits
SEC3/25/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/24/2026material
10-K filing
SEC2/24/2026
8-K — Other events, Exhibits
SEC2/19/2026material
8-K — Other events, Exhibits
SEC1/22/2026material

2025

8-K — Other events, Exhibits
SEC12/31/2025material
8-K — Results of operations, Reg FD disclosure
SEC11/4/2025material
10-Q filing
SEC11/4/2025
8-K — Termination of agreement, Exhibits
SEC10/14/2025material
8-K — Executive/director change, Exhibits
SEC10/6/2025material
8-K — Other events, Exhibits
SEC9/10/2025material
8-K — Results of operations, Reg FD disclosure
SEC7/31/2025material
10-Q filing
SEC7/31/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.